Dr. David Reardon (Clinical Director, Center for Neuro-Oncology) in collaboration with the Novina Lab received the Alliance for Cancer Gene Therapy (ACGT) 2018 Innovator Grant! “This work represents the next generation of gene therapies,” noted Margaret Cianci, executive director of ACGT. “Two of the three grants fund crucial research leading to the development of cancer vaccines, among the most promising forms of gene therapy. These vaccines are not like traditional vaccines – no live pathogens are used to establish a barrier to the disease. Instead, cancer vaccines contain inactive viruses or a patient’s modified cancer cells to penetrate just the cancer and then serve as a beacon for the immune system to attack. Advances in medical technology have also made it possible to customize vaccines to DNA and to specific forms of cancer. We are very excited about this research and hope to see major steps forward in the treatment of solid cancers with these different methodologies.” Read more about the grant here.